Every year in the UK alone, norovirus outbreaks cost the NHS over £100 million and force the closure of more than 15,000 hospital beds. This research tackles a fundamental gap in knowledge: how the virus’s key structural protein, VP1, actually works. Norovirus has no treatment or vaccine. VP1 is the protein that forms the virus’s outer shell, delivers its genome into cells to start infection, and is the first thing the immune system sees during an infection. Yet scientists do not fully understand how VP1 performs these different jobs at each step of the virus life cycle. This is fundamental science. The project will map how VP1 functions during infection and spread between cells. If successful, the work will not produce a drug or vaccine directly. Instead, it will provide the molecular understanding needed to design future treatments. Similar fundamental research on viral capsid proteins has previously enabled the development of vaccines for HPV and hepatitis B. A clearer picture of VP1’s role could eventually lead to antiviral drugs that block norovirus from entering cells, or to more effective vaccine targets—reducing the burden on hospitals and saving lives in vulnerable populations worldwide.
View original technical description
Human noroviruses, commonly known as "winter vomiting disease" are a major cause of gastroenteritis worldwide for which there is no treatment or preventative strategies available. Outbreaks of norovirus often occur in partly enclosed communities, most notably hospital wards and care homes where closes and restrictions apply a drain on healthcare services. In the UK alone every year, norovirus outbreaks result in the loss of over 15,000 bed days and a financial burden of over £100 million. Norovirus infection is estimated to result in the loss of over 200,000 lives each year, primarily in the most vulnerable populations such as found in lower and middle income countries (LIMC), the young and elderly and those with a compromised immune system. The disease-causing viruses are small, each one consisting of the viral genome enclosed within a protein capsid comprised mostly of the major viral structural protein VP1. This is a key protein in virus replication. It is responsible for the delivery of the virus genome to start an infection and production of more virus to spread infection both between cells and between people. Importantly, as the major constituent of viral capsids, VP1 is important for generating an anti-viral immune response and is the first viral component the immune system experiences during when a person become infected. This research will study how VP1 functions at different steps of the virus life-cycle to start infection and spread infection to new cells. Understanding these fundamental processes will aid the development of future approaches to disease control.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know